Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 76, Issue 2, 2007, Pages 304-312

  Rayman, Gerrard ^a   Profozic, Velimir ^b   Middle, Michelle ^c  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c South Africa Clinical Trials Ltd   (South Africa)

Author keywords

Glycaemic; Insulin glulisine; Type 2 diabetes (T2DM)

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN GLULISINE; ISOPHANE INSULIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE;

ADULT; AGED; ARTICLE; CHRONOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 33947098842     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.09.006     Document Type: Article

References (19)

1. Stratton I., Adler A., Neil A., Matthews D., Manley S., Cull C., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
2. World Health Organization, Diabetes mellitus, Fact Sheet No. 138 (2002).
3. Riddle M.C. Timely initiation of basal insulin. Am. J. Med. 116 (2004) 3S-9S
4. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
5. Monnier L., and Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr. Pract. 12 Suppl. 1 (2006) 42-46
6. Becker R., Frick A., Wessels D., and Scholtz H. Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine-a novel, rapid-acting, human insulin analogue. Diabetologia 46 (2003) (Abstract 775)
7. Becker R., Frick A., Kapitza C., Heise T., and Rave K. Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes 53 (2004) (Abstract 503)
8. Burger F., Scholtz H., Frick A., and Becker R. Pharmacodynamics and pharmacokinetics of insulin glulisine versus insulin lispro and regular human insulin in patients with Type 1 diabetes. Diabetes 53 (2004) A557 (Abstract 2350-PO)
9. Garg S.K., Ellis S.L., and Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin. Pharmacother. 6 (2005) 643-651
10. Becker R.H., Frick A.D., Burger F., Scholtz H., and Potgieter J.H. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp. Clin. Endocrinol. Diabetes 113 (2005) 292-297
11. Danne T., Becker R.H., Heise T., Bittner C., Frick A.D., and Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 28 (2005) 2100-2105
12. Heinemann L., Heise T., Jorgensen L.N., and Starke A.A. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabetes Med. 10 (1993) 535-539
13. Garg S.K., Rosenstock J., and Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr. Pract. 11 (2005) 11-17
14. Rave K., Klein O., Frick A., and Becker R. Advantage of pre-meal injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 29 (2006) 1812-1817
15. DECODE Study Group, the European Diabetes Epidemiology Group, Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria, Arch. Intern. Med. 161 (2001) 397-405.
16. Fritsche A., Schweitzer M., Haring H.-U., and Group S. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 138 (2003) 952-959
17. Dailey G., Rosenstock J., Moses R., and Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27 (2004) 2363-2368
18. Dreyer M., Prager R., Robinson A., Busch K., Ellis G., Souhami E., et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm. Metab. Res. 37 (2005) 702-707
19. Frick A., Becker R., Wessels D., and Scholtz H. Pharmacokinetic and glucodynamic profiles of insulin glulisine: an evaluation following subcutaneous administration at various injection sites. Diabetologia 46 (2003) (Abstract 776)